Literature DB >> 10097998

Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.

N A Dartnall1, J P Holmes, S N Morgan, C J McDougle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10097998     DOI： 10.1023/a:1025926817928

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN： 0162-3257


× No keyword cloud information.
  15 in total

1.  Case study: risperidone-induced hepatotoxicity in pediatric patients.

Authors:  S Kumra; D Herion; L K Jacobsen; C Briguglia; D Grothe
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-05       Impact factor: 8.829

2.  Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.

Authors:  C J McDougle; J P Holmes; M R Bronson; G M Anderson; F R Volkmar; L H Price; D J Cohen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-05       Impact factor: 8.829

3.  Case study: risperidone treatment of children and adolescents with developmental disorders.

Authors:  A Hardan; K Johnson; C Johnson; B Hrecznyj
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1996-11       Impact factor: 8.829

4.  Fluoxetine treatment of children and adults with autistic disorder and mental retardation.

Authors:  E H Cook; R Rowlett; C Jaselskis; B L Leventhal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1992-07       Impact factor: 8.829

5.  A scatter plot for identifying stimulus control of problem behavior.

Authors:  P E Touchette; R F MacDonald; S N Langer
Journal:  J Appl Behav Anal       Date:  1985

6.  A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

Authors:  C J McDougle; S T Naylor; D J Cohen; F R Volkmar; G R Heninger; L H Price
Journal:  Arch Gen Psychiatry       Date:  1996-11

7.  Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study.

Authors:  R Vanden Borre; R Vermote; M Buttiëns; P Thiry; G Dierick; J Geutjens; G Sieben; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1993-03       Impact factor: 6.392

8.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

Authors:  G Chouinard; B Jones; G Remington; D Bloom; D Addington; G W MacEwan; A Labelle; L Beauclair; W Arnott
Journal:  J Clin Psychopharmacol       Date:  1993-02       Impact factor: 3.153

Review 9.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Authors:  S Grant; A Fitton
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

10.  Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.

Authors:  J E Leysen; P M Janssen; A A Megens; A Schotte
Journal:  J Clin Psychiatry       Date:  1994-05       Impact factor: 4.384
View more
  4 in total

1.  Risperidone treatment in 12 children with developmental disorders and attention-deficit/hyperactivity disorder.

Authors:  Valsamma Eapen; A K Gururaj
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

2.  Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders.

Authors:  Carllo Gagiano; Stephen Read; Lilian Thorpe; Mariëlle Eerdekens; Ilse Van Hove
Journal:  Psychopharmacology (Berl)       Date:  2005-01-25       Impact factor: 4.530

Review 3.  Risperidone for autism spectrum disorder.

Authors:  O S Jesner; M Aref-Adib; E Coren
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Off-label indications for atypical antipsychotics: A systematic review.

Authors:  Konstantinos N Fountoulakis; Ioannis Nimatoudis; Apostolos Iacovides; George Kaprinis
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.